» Articles » PMID: 25549093

Pharmacotherapy for Adverse Events Reduces the Length of Hospital Stay in Patients Admitted to Otolaryngology Ward: a Single Arm Intervention Study

Overview
Journal PLoS One
Date 2014 Dec 31
PMID 25549093
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To determine whether adverse events extend the duration of hospitalization, and to evaluate the effectiveness of medical intervention in ameliorating adverse events and reducing the prolonged hospital stay associated with adverse events.

Methods: A single arm intervention study was conducted from October 2012 to March 2014 in the otolaryngology ward of a 614-bed, university-affiliated hospital. Adverse events were monitored daily by physicians, pharmacists and nurses, and recorded in the electronic medical chart for each patient. Appropriate drug management of adverse events was performed by physicians in liaison with pharmacists. The Kaplan-Meier method was used to assess the length of hospitalization of patients who underwent medical intervention for adverse events.

Results: Of 571 patients admitted to the otolaryngology ward in a year, 219 patients (38.4%) experienced adverse events of grade ≥2. The duration of hospitalization was affected by the grade of adverse events, with a mean duration of hospital stay of 9.2, 17.2, 28.3 and 47.0 days for grades 0, 1, 2, and 3-4, respectively. Medical intervention lowered the incidence of grade ≥2 adverse events to 14.5%. The length of hospitalization was significantly shorter in patients who showed an improvement of adverse events after medical intervention than those who did not (26.4 days vs. 41.6 days, hazard ratio 1.687, 95% confidence interval: 1.260-2.259, P<0.001). A multivariate Cox proportional hazard analysis indicated that insomnia, constipation, nausea/vomiting, infection, non-cancer pain, oral mucositis, odynophagia and neutropenia were significant risk factors for prolongation of hospital stay.

Conclusion: Patients who experienced adverse events are at high risk of prolonged hospitalization. Medical intervention for adverse events was found to be effective in reducing the length of hospital stay associated with adverse events.

Citing Articles

Medication reconciliation by pharmacists for pre-admission patients improves patient safety.

Yamada Y, Kobayashi R, Yamamoto T, Fujii H, Iihara H, Hiroko K J Pharm Health Care Sci. 2024; 10(1):19.

PMID: 38671535 PMC: 11046811. DOI: 10.1186/s40780-024-00340-2.


Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy.

Iihara H, Hirose C, Funaguchi N, Endo J, Ito F, Yanase K Mol Clin Oncol. 2021; 14(6):116.

PMID: 33903822 PMC: 8060846. DOI: 10.3892/mco.2021.2278.


Efficacy Oral Glutamine to Prevent Oral Mucositis and Reduce Hospital Costs During Chemotherapy in Children with Acute Lymphoblastic Leukemia.

Widjaja N, Pratama A, Prihaningtyas R, Irawan R, Ugrasena I Asian Pac J Cancer Prev. 2020; 21(7):2117-2121.

PMID: 32711440 PMC: 7573404. DOI: 10.31557/APJCP.2020.21.7.2117.


A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders.

Hewlings S, Kalman D Nutrients. 2020; 12(3).

PMID: 32121367 PMC: 7146259. DOI: 10.3390/nu12030665.


Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy.

Hayashi H, Kobayashi R, Suzuki A, Yamada Y, Ishida M, Shakui T Med Oncol. 2016; 33(8):91.

PMID: 27418192 PMC: 4945687. DOI: 10.1007/s12032-016-0795-z.


References
1.
Mercadante S . Management of cancer pain. Intern Emerg Med. 2010; 5 Suppl 1:S31-5. DOI: 10.1007/s11739-010-0448-8. View

2.
Brennan T, Leape L, Laird N, Hebert L, Localio A, Lawthers A . Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991; 324(6):370-6. DOI: 10.1056/NEJM199102073240604. View

3.
Schilling M, Parks C, Deeter R . Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med. 2012; 2(5):859-866. PMC: 3440789. DOI: 10.3892/etm.2011.312. View

4.
Sonis S, Oster G, Fuchs H, Bellm L, BRADFORD W, Edelsberg J . Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001; 19(8):2201-5. DOI: 10.1200/JCO.2001.19.8.2201. View

5.
Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J . Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109(5):820-31. DOI: 10.1002/cncr.22484. View